Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most undervalued stocks.

Biogen Inc. (NASDAQ:BIIB) is a global biotechnology leader known for its treatments in multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s disease, and an expanding portfolio in rare and pediatric neurological disorders.

On June 18, 2025, Biogen Inc. (NASDAQ:BIIB) began a global Phase 3 pediatric trial of omaveloxolone for Friedreich’s ataxia, a rare inherited neurodegenerative disease. The company is actively diversifying beyond its traditional MS business, which has seen declining revenues due to increased competition. Now, 45% of its revenue comes from non-MS products, including Skyclarys for Friedreich’s ataxia and Leqembi for early Alzheimer’s disease. This strategic shift has prompted some analysts to consider Biogen among the most undervalued stocks in biotech, given its deep pipeline and potential in rare disease markets.

The company is also progressing felzartamab, an antibody therapy acquired through HI-Bio, into Phase 3 trials for IgA nephropathy and kidney transplant rejection. Early results show promising, sustained effects in kidney function, positioning felzartamab as a potential new treatment standard in immune-mediated diseases.

In February 2025, Biogen Inc. (NASDAQ:BIIB) formed a partnership with Stoke Therapeutics to develop zorevunersen for Dravet syndrome, a rare genetic epilepsy, further strengthening its rare disease pipeline through external innovation.

The corporation’s international expansion of Skyclarys into the U.K. and Brazil and its deepening focus on underserved neurological conditions reflect a clear strategic shift. As CEO Chris Viehbacher put it, “There’s a new Biogen emerging”—one that’s reshaping its future through targeted innovation in rare and pediatric neuroscience.

While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.